Giardiasis is an intestinal parasitic infection requiring specific pharmacological treatment to achieve parasite clearance and symptom resolution. The first-line protocol defines the preferred therapeutic approach, including the agent of choice and the range of effective alternatives.

Treatment Approach

First-line management is pharmacological. One specific oral agent is considered the treatment of choice in the United States for both adults and children, with a standard multi-day course expected to resolve infection in the majority of cases. Several distinct alternatives are available, ranging from single-dose options to multi-day regimens, to accommodate different clinical situations.

The complete regimen — including all agents, sequencing, and dosing by age — is available in the full protocol.

References

DOI: 10.1128/CMR.14.1.114–128.2001

The most effective agents for therapy of giardiasis are single doses of tinidazole or ornidazole, 5 to 7 days of quinacrine, and 5 to 7 days of metronidazole.
Therefore, the treatment of choice in the United States for both adults and children is metronidazole.
A standard course of 5 to 7 days should effectively treat 90% or more of infected individuals.
Furazolidone is an effective alternative but requires 7 to 10 days of treatment four times a day, which will probably affect compliance.
Of the newer therapeutics, albendazole in a 5-day regimen seems most promising, but additional studies are needed.
It can be expected that parasites will be cleared from the stool in 3 to 5 days and that symptoms will resolve in 5 to 7 days.

View source ↗

What Is the Treatment for Giardiasis? First-Line Protocol

References